Alembic Pharmaceuticals receives approval for Darifenacin ER Tablets
From USFDA
Alembic Pharmaceuticals has received USFDA approval for Darifenacin Extended-Release Tablets, 7.5 mg and 15 mg. Darifenacin Extended-Release Tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content